1YG0 Stock Overview
A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.72 |
| 52 Week High | SEK 1.34 |
| 52 Week Low | SEK 0.008 |
| Beta | 1.03 |
| 11 Month Change | -16.87% |
| 3 Month Change | 39.92% |
| 1 Year Change | 25.78% |
| 33 Year Change | -91.55% |
| 5 Year Change | -96.42% |
| Change since IPO | -94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1YG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.0% | -2.1% | -0.5% |
| 1Y | 25.8% | -19.2% | 1.6% |
Return vs Industry: 1YG0 exceeded the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 1YG0 exceeded the German Market which returned 2.4% over the past year.
Price Volatility
| 1YG0 volatility | |
|---|---|
| 1YG0 Average Weekly Movement | 79.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1YG0's share price has been volatile over the past 3 months.
Volatility Over Time: 1YG0's weekly volatility has decreased from 172% to 79% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 28 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| 1YG0 fundamental statistics | |
|---|---|
| Market cap | €36.87m |
| Earnings (TTM) | -€9.42m |
| Revenue (TTM) | €2.51m |
14.7x
P/S Ratio-3.9x
P/E RatioIs 1YG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1YG0 income statement (TTM) | |
|---|---|
| Revenue | SEK 28.49m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 28.49m |
| Other Expenses | SEK 135.55m |
| Earnings | -SEK 107.06m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -375.83% |
| Debt/Equity Ratio | 0.1% |
How did 1YG0 perform over the long term?
See historical performance and comparison